Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study.
Alcaraz A, González-López R, Morote J, de la Piedra C, Meseguer C, Esteban E, Climent M, González-Gragera B, Alvarez-Ossorio JL, Chirivella I, Mellado B, Lara PC, Vázquez F, Contreras JA, Carles J, Murias A, Calderero V, Comet-Batlle J, González-Del Alba A, León-Mateos L, Mañas A, Segarra J, Lassa A, González-Enguita C, Méndez MJ, Samper P, Unda M, Mahillo-Fernández I, Bellmunt J; TUGAMO GROUP. Alcaraz A, et al. Among authors: contreras ja. Br J Cancer. 2013 Jul 9;109(1):121-30. doi: 10.1038/bjc.2013.272. Epub 2013 Jun 25. Br J Cancer. 2013. PMID: 23799855 Free PMC article.
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study.
de la Piedra C, Alcaraz A, Bellmunt J, Meseguer C, Gómez-Caamano A, Ribal MJ, Vázquez F, Anido U, Samper P, Esteban E, Álvarez-Ossorio JL, Lara PC, San José LA, Contreras JA, del Alba AG, González-Gragera B, Tabernero AJ, González-Enguita C, Fernández JM, García-Escudero A, Gómez-Veiga F, Méndez MJ, Segarra J, Virizuela JA, Carles J, Lassa A, Calderero V, Constela M, Delgado D, Mañas A, Murias A, Reynes G, Rodriguez B, Rubio G, Sánchez E, Unda M, Solsona E, Martínez-Javaloyas JM, Comet-Batlle J, Quicios C, Martín-Fernández M, Mahillo-Fernández I, Morote J. de la Piedra C, et al. Among authors: contreras ja. Br J Cancer. 2013 Jun 25;108(12):2565-72. doi: 10.1038/bjc.2013.270. Epub 2013 May 30. Br J Cancer. 2013. PMID: 23722472 Free PMC article. Clinical Trial.
HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies.
Khalaf DJ, Aragón IM, Annala M, Lozano R, Taavitsainen S, Lorente D, Finch DL, Romero-Laorden N, Vergidis J, Cendón Y, Oja C, Pacheco MI, Zulfiqar M; PROREPAIR-B investigators; Gleave ME, Wyatt AW, Olmos D, Chi KN, Castro E. Khalaf DJ, et al. Ann Oncol. 2020 Sep;31(9):1186-1197. doi: 10.1016/j.annonc.2020.06.006. Epub 2020 Jun 20. Ann Oncol. 2020. PMID: 32574722 Free article. Clinical Trial.
Music as Medicine: A Concept Analysis.
Contreras JA. Contreras JA. Creat Nurs. 2022 Nov 10;28(4):234-239. doi: 10.1891/CN-2022-0034. Creat Nurs. 2022. PMID: 36411048
81 results